Sunshine Biopharma Inc. (SBFM) stock
SBFMNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFMW
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3099% below fair value
$2.84+0.09 (+3.27%)
Close on Nov 12, 2026Market cap $790.42KP/E –Yield –
Sunshine Biopharma operating margin
Operating margin is operating income as a percentage of revenue.
Sunshine Biopharma's operating margin for the twelve months ending Sep 30, 2026 was -17.2%. For fiscal 2025 it was -17.2%, against -16.7% the year before. The highest annual figure on record is -16.7% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -17.2% | −0.5 |
| FY2024 | Dec 31, 2024 | -16.7% | +3.2 |
| FY2023 | Dec 31, 2023 | -19.9% | +601.5 |
| FY2022 | Dec 31, 2022 | -621.3% | +446.9 |
| FY2021 | Dec 31, 2021 | -1068.2% | −260.4 |
| FY2020 | Dec 31, 2020 | -807.8% | +2230.1 |
| FY2019 | Dec 31, 2019 | -3037.9% | +42645.8 |
| FY2015 | Dec 31, 2015 | -45683.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -13.7% | −2.1 |
| Q2 FY2026 | Jun 30, 2026 | -17.4% | +4.4 |
| Q1 FY2026 | Mar 31, 2026 | -17.3% | −2.7 |
| Q4 FY2025 | Dec 31, 2025 | -20.9% | +0.4 |
| Q3 FY2025 | Sep 30, 2025 | -11.5% | +1.6 |
| Q2 FY2025 | Jun 30, 2025 | -21.8% | −8.2 |
| Q1 FY2025 | Mar 31, 2025 | -14.6% | +3.4 |
| Q4 FY2024 | Dec 31, 2024 | -21.2% | −5.8 |
| Q3 FY2024 | Sep 30, 2024 | -13.1% | −0.0 |
| Q2 FY2024 | Jun 30, 2024 | -13.6% | +4.6 |
| Q1 FY2024 | Mar 31, 2024 | -17.9% | +19.5 |
| Q4 FY2023 | Dec 31, 2023 | -15.5% | +577.6 |
| Q3 FY2023 | Sep 30, 2023 | -13.1% | +1280.5 |
| Q2 FY2023 | Jun 30, 2023 | -18.2% | +444.7 |
| Q1 FY2023 | Mar 31, 2023 | -37.4% | +960.1 |
| Q4 FY2022 | Dec 31, 2022 | -593.0% | −264.5 |
| Q3 FY2022 | Sep 30, 2022 | -1293.6% | −308.5 |
| Q2 FY2022 | Jun 30, 2022 | -462.9% | +272.0 |
| Q1 FY2022 | Mar 31, 2022 | -997.5% | +2187.0 |
| Q4 FY2021 | Dec 31, 2021 | -328.5% | +897.0 |
| Q3 FY2021 | Sep 30, 2021 | -985.1% | −592.8 |
| Q2 FY2021 | Jun 30, 2021 | -735.0% | +114.0 |
| Q1 FY2021 | Mar 31, 2021 | -3184.5% | −2844.9 |
| Q4 FY2020 | Dec 31, 2020 | -1225.6% | +1148.3 |
| Q3 FY2020 | Sep 30, 2020 | -392.3% | +2373.7 |
| Q2 FY2020 | Jun 30, 2020 | -848.9% | +1333.6 |
| Q1 FY2020 | Mar 31, 2020 | -339.6% | +58985.2 |
| Q4 FY2019 | Dec 31, 2019 | -2373.9% | −2191.1 |
| Q3 FY2019 | Sep 30, 2019 | -2766.0% | – |
| Q2 FY2019 | Jun 30, 2019 | -2182.6% | – |
| Q1 FY2019 | Mar 31, 2019 | -59324.8% | – |
| Q1 FY2018 | Mar 31, 2018 | -182.8% | – |
See a number that looks wrong?